Product Description: MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC50=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos[1][2][3][4][5].
Applications: Cancer-programmed cell death
Formula: C35H49F2N7O4
Citations: Acta Pharmacol Sin. 2021 Apr 13./Cell Death Dis. 2022 Sep 6;13(9):770./J Mol Endocrinol. 2021 Jan;66(1):45-57./Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966.
References: [1]Karatas H, et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2013, 135(2), 669-682./[2]Townsend E C. Development of a Novel Inhibitor to the Conserved, Developmental Regulator, WDR5, for Treatment of Acute Leukemia[D]. , 2012./[3]Wang D, et al. MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5[J]. Journal of Experimental & Clinical Cancer Research, 2024, 43(1): 272./[4]Hara D, et al. Inhibition of H3K4 Trimethylation Ameliorates Peritoneal Fibrosis and Senescence: FR-PO456[J]. Journal of the American Society of Nephrology, 2022, 33(11S): 447-448./[5]Zhang Z, et al. Down-regulation of H3K4me3 by MM-102 facilitates epigenetic reprogramming of porcine somatic cell nuclear transfer embryos[J]. Cellular Physiology and Biochemistry, 2018, 45(4): 1529-1540.
CAS Number: 1417329-24-8
Molecular Weight: 669.80
Compound Purity: 99.39
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: Apoptosis;Interleukin Related;NF-κB;TNF Receptor;WDR5
English
Deutsch
